Malaria vaccine on the cards?India.Com HealthIt travels all through his blood stream to reach the liver. In the liver the parasite matures and multiplies. Some of the parasites stay there whereas the other parasites move out from the liver attacking re…
Destination Disney: Young transplant patient represents SC – ABC NEWS 4
Destination Disney: Young transplant patient represents SCABC NEWS 4On January 25, Morgan underwent a heart transplant surgery. The surgery lasted the better part of eight hours. Much like the little girl we met then and the little girl we saw tip-toei…
Gilotrif (Non-Small Cell Lung Cancer) – Forecast and Market Analysis to 2022 … – SBWire (press release)
Gilotrif (Non-Small Cell Lung Cancer) – Forecast and Market Analysis to 2022 …SBWire (press release)Boston, MA — (SBWIRE) — 10/08/2013 — Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men an…
Aegis Capital Keeps Buy on Acorda (ACOR); GGF2 Progress In-Line, Q3 Should … – StreetInsider.com (subscription)
Aegis Capital Keeps Buy on Acorda (ACOR); GGF2 Progress In-Line, Q3 Should …StreetInsider.com (subscription)The trial design included seven cohorts of six participants each, four of whom received GGF2 and two of whom received placebo at each dose. In…
ECC: Everolimus Effective in Advanced Papillary Renal Cell Carcinoma – Cancer Network
|
ECC: Everolimus Effective in Advanced Papillary Renal Cell Carcinoma
Cancer Network “Our clinical findings are encouraging and suggest that everolimus may represent a new treatment option,” Escudier said. In the open-label, phase II RAPTOR trial, Escudier and colleagues from six countries enrolled 92 treatment-naive patients with ECOG … |
Florida Hospital Tampa Earns Advanced Certification for Heart Failure and … – PR Web (press release)
PR Web (press release) |
Florida Hospital Tampa Earns Advanced Certification for Heart Failure and …
PR Web (press release) Florida Hospital Tampa is one of only five hospitals in the state to receive advanced certification for heart failure and is proud to earn the Joint Commission’s Gold Seal of Approval for both heart and stroke programs. Share on Twitter Share on … |
Nice recommends Roche's MabThera – CSL Recruitment
|
Nice recommends Roche’s MabThera
CSL Recruitment New draft guidance from the National Institute for Health and Care Excellence (Nice) has recommended the Roche drug MabThera (rituximab) as a treatment for adults with a rare type of vasculitis. The drug is licensed for bringing on remission in people … |
Red wine compound to treat heart condition – Times of India
Times of IndiaRed wine compound to treat heart conditionTimes of IndiaFaculty of Medicine and Dentistry researcher Peter Light and his colleagues discovered that new resveratrol-based drugs they created that were used in the lab, helped regulate electr…
Acorda Therapeutics Begins Second Phase 1 GGF2 Trial In Heart Failure – RTT News
Acorda Therapeutics Begins Second Phase 1 GGF2 Trial In Heart FailureRTT NewsAcorda Therapeutics Inc. (ACOR: Quote) today announced that the first patient has been enrolled in the second trial of Glial Growth Factor 2 or GGF2. This Phase 1b single-infu…
Acorda Therapeutics Begins Second Phase 1 GGF2 Trial In Heart Failure – NASDAQ
Acorda Therapeutics Begins Second Phase 1 GGF2 Trial In Heart FailureNASDAQ(RTTNews.com) – Acorda Therapeutics Inc. ( ACOR ) today announced that the first patient has been enrolled in the second trial of Glial Growth Factor 2 or GGF2. This Phase 1b si…